Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK.
Saved in:
| Title: | Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. |
|---|---|
| Authors: | Chetty M; Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. Mersha.Chetty@sanofi.com., Costello P; Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK., Yarnoff B; Evidera Inc., Wilmington, NC, USA., Musci R; Evidera Inc., San Francisco, CA, USA., Ghemmouri M; Sanofi, Lyon, France. |
| Source: | Infectious diseases and therapy [Infect Dis Ther] 2025 Aug; Vol. 14 (8), pp. 1953-1972. Date of Electronic Publication: 2025 Jul 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8229 |
|---|---|
| DOI: | 10.1007/s40121-025-01194-3 |
